EPO Protein (AA 27-192)

Catalog No. ABIN2666935

This Recombinant EPO protein is produced in CHO Cells.

Quick Overview for EPO Protein (AA 27-192) (ABIN2666935)

Target: EPO (Erythropoietin (EPO))

Protein Type: Recombinant

Biological Activity: Active

Origin: Mouse

Source: CHO Cells

Application: Flow Cytometry (FACS)

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 27-192

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: ED50 = 0.5 - 2.5 ng/ml, corresponding to a specific activity of 0.4 - 2 x 106 units/mg, as determined by the dose dependent stimulation of TF-1 cells proliferation.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Target Details

Target: EPO (Erythropoietin (EPO))

Alternative Name: Erythropoietin

Target Type: Hormone

Background: Mouse Erythropoietin (EPO) was initially cloned from mouse genomic libraries using human and monkey cDNA probes. Mouse and human EPO are 80 % identical at amino acid and nucleotide levels. EPO is a glycoprotein composed of 40-60 % carbohydrates, and its molecular weight varies from 30-34 kD depending on the carbohydrate percentage. Hypoxia induces erythropoiesis, and hypoxia inducible factor (HIF) is directly involved in EPO expression. HIF is a heterodimer (HIF-1α, HIF-2α, and β subunits) transcription factor, and it is regulated by HIF-prolyl hydroxylase (HIF-PH) that hydroxylates the α subunits, targeting them for ubiquitination and subsequent degradation. HIF-PH is a sensor of levels of iron, oxygen, and metabolic activity. High levels of HIF protein induce EPO production in the kidney and liver, and mobilization of iron to support erythropoiesis. EPO binds to the EPOR, and transcripts of this receptor have been detected in non-erythroid precursors such as endothelial cells and renal proximal epithelial cells, nevertheless, it has been published that functional erythropoietin receptor is not detected in endothelial, cardiac, neuronal, and renal cells. Several transcriptions factors play a role in the expression of EPOR such as GATA 1, Friend of GATA (Fog1), and the erythroid specific factor SCL/Tal 1. EPO has been used in the treatment of anemia associated with chronic kidney disease, cancer patients on chemotherapy, and antiviral HIV therapy.

Molecular Weight: The 166 amino acid recombinant protein has a predicted molecular mass of approximately 18.6 kDa. The DTT-reduced and non-reduced protein migrate at approximately 35-50 kDa and 33-48 kDa by SDS-PAGE respectively. The N-terminal amino acid is Ala.

Pathways: JAK-STAT Signaling, Hormone Activity, Negative Regulation of intrinsic apoptotic Signaling, Negative Regulation of Transporter Activity